COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB COMPARED TO USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN THE CZECH REPUBLIC

被引：3
|
作者：
Klimes, J. [1 ]
Mollon, P. [2 ]
Graham, C. [3 ]
Rajnoch, J. [1 ]
Dostal, F. [1 ]
Skalicky, D. [1 ]
Jordan, P. [1 ]
Depta, J. [2 ]
机构：
[1] Novartis Sro, Prague, Czech Republic
[2] Novartis Pharma AG, Basel, Switzerland
[3] RTI Hlth Solut, Res Triangle Pk, NC USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.575
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS51
引用
收藏
页码：A424 / A424
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF SECUKINUMAB COMPARED WITH USTEKINUMAB AND ETANERCEPT FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
    Tzanetakos, C.
    Kourlaba, G.
    Chatzikou, M.
    Antoniou, C.
    Ioannidis, D.
    Lefaki, I
    Petridis, A.
    Rigopoulos, D.
    Roussaki-Schulze, A.
    Sotiriadis, D.
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A569 - A569
  • [2] Cost-effectiveness of secukinumab compared with ustekinumab and etanercept for the treatment of moderate-to-severe plaque psoriasis in Greece
    Tzanetakos, C.
    Kourlaba, G.
    Hatzikou, M.
    Antoniou, C.
    Ioannides, D.
    Lefaki, I.
    Petridis, A.
    Rigopoulos, D.
    Roussaki-Schulze, V.
    Sotiriadis, D.
    Maniadakis, N.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 61 - 62
  • [3] COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB COMPARED TO CURRENT BIOLOGICS SEQUENCES FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN FRANCE
    Duteil, E.
    Cariou, C.
    Schmidt, A.
    Benjamin, K.
    Duco, J.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A589 - A589
  • [4] MODELING THE COST-EFFECTIVENESS OF USTEKINUMAB FOR MODERATE TO SEVERE PLAQUE PSORIASIS IN US
    Verma, S.
    Dharmarajan, S.
    Yang, Y.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A147 - A147
  • [5] COST-EFFECTIVENESS OF USTEKINUMAB IN THE MANAGEMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN MEXICO
    Valencia-Mendoza, A.
    Hernandez-Garduno, A.
    Puig, A.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A513 - A514
  • [6] COST-EFFECTIVENESS OF SECUKINUMAB IN MODERATE TO SEVERE PSORIASIS COMPARED WITH OTHER BIOLOGICS IN GERMANY
    Graham, C. N.
    McBride, D.
    Miles, L.
    Gilloteau, I
    O'Neill, C. B.
    Neidhardt, K.
    Augustin, M.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A157 - A157
  • [7] The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis
    Rouse, Nicole C.
    Farhangian, Michael E.
    Wehausen, Brooke
    Feldman, Steven R.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (06) : 877 - 884
  • [8] A COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB 300 MG VS CURRENT THERAPIES FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN ITALY
    D'Ausilio, A.
    Aiello, A.
    Daniel, F.
    Graham, C.
    Roccia, A.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A424 - A424
  • [9] Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany
    Augustin, M.
    McBride, D.
    Gilloteau, I.
    O'Neill, C.
    Neidhardt, K.
    Graham, C. N.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (12) : 2191 - 2199
  • [10] ASSESSMENT OF THE COST-EFFECTIVENESS OF SECUKINUMAB VERSUS RISANKIZUMAB FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN THE UK
    Moreno, S.
    Walsh, S.
    Khanna, P. J.
    Jain, M.
    Tanova-Yotova, N.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S89 - S89
12345